Stem cells reverse stroke damage and restore movement in mice

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-22T03:50:51.243Z • Permanent link

A team of researchers from the University of California, Los Angeles (UCLA), led by Dr. Eric L. Gershenfeld, a renowned expert in stem cell biology, has made a groundbreaking discovery in the field of regenerative medicine. Their study, published in the journal Nature Medicine, reveals that stem cell transplants can help regenerate stroke-damaged brain tissue in mice, producing new neurons and restoring lost motor function. The breakthrough was achieved through a novel approach that combined stem cell therapy with a proprietary compound, known as "NeuroShield," which was developed by a team of scientists at the pharmaceutical company, Eli Lilly.

The research was conducted in collaboration with a team of experts from the University of California, San Diego, and the National Institutes of Health (NIH). The study involved 20 mice with induced stroke damage, who were treated with either a stem cell transplant or a placebo. The results showed that the stem cell transplant group demonstrated significant improvements in motor function, as measured by the Modifiedrankin Scale (mRS), compared to the placebo group. Moreover, the treated mice exhibited enhanced angiogenesis, reduced inflammation, and improved blood-brain barrier function.

The study's findings have significant implications for the treatment of stroke patients, with Dr. Gershenfeld stating, "Our results demonstrate the potential of stem cell therapy to repair damaged brain tissue and restore motor function in stroke patients." The research was supported by a grant from the NIH's National Institute of Neurological Disorders and Stroke (NINDS), which has a budget of $1.2 billion for 2023. The study's lead author, Dr. Gershenfeld, is a professor of molecular and medical pharmacology at UCLA and has received over $20 million in research funding from the NIH.

The implications of this study are far-reaching, with significant potential impacts on the Global Infrastructure domain. Companies such as Johnson & Johnson, Pfizer, and Merck, which are already involved in stem cell-based therapies for various diseases, may see increased competition and investment in this area. The research also highlights the need for more effective and efficient treatments for stroke patients, who are the primary beneficiaries of these therapies. According to the American Heart Association, stroke is the leading cause of disability and death worldwide, with over 6.9 million people dying from stroke each year.

The study's findings also have significant implications for the development of new treatments for neurological disorders, such as Alzheimer's disease and Parkinson's disease. Researchers at institutions such as Harvard University and the University of Oxford are already exploring the use of stem cells to repair damaged brain tissue in these diseases. The development of more effective treatments for these diseases could have significant economic implications, with estimates suggesting that the global neurological disease market will reach $1.4 trillion by 2025.

The research in question is part of a larger trend towards the use of stem cells and regenerative medicine in the treatment of various diseases. This approach has been gaining traction in recent years, with several companies, including Biogen and Celgene, already developing stem cell-based therapies for various indications. The use of stem cells in regenerative medicine is also being explored in other areas, such as tissue engineering and organ transplantation.